Business
Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
Fort Lee, NJ, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the appointment of Juan Sanchez, MD, to its Board of Directors. Dr. Sanchez is a seasoned biotech executive with expertise in industry, capital markets and medicine, having most recently served as Vice President of Cor
About this update from Nuvectis Pharma, Inc.
[{"type":"image","alt":"Nuvectis Pharma, Inc.","displaySize":"","headline":null,"caption":"Nuvectis Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":152,"url":"https://media.zenfs.com/en/globenewswire.com/989394dc1a2c2d302d391f5a4d69410d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/W.V.VnmdN5OtxNT977ZzKg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/989394dc1a2c2d302d391f5a4d69410d","width":300,"height":152}},"lazy":false},{"type":"text","content":"Fort Lee, NJ, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the appointment of Juan Sanchez, MD, to its Board of Directors.","length":345,"tagName":"p"},{"type":"text","content":"Dr. Sanchez is a seasoned biotech executive with expertise in industry, capital markets and medicine, having most recently served as Vice President of Corporate Communications and Investor Relations at Intra-Cellular Therapies, acquired by Johnson & Johnson in April 2025 for $14.6 billion.","length":294,"tagName":"p"},{"type":"text","content":"Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “We are excited to welcome Dr. Juan Sanchez to the Nuvectis Board of Directors. As we enter the next stage of growth, with the start of the Phase 1b program for NXP900, we believe Juan brings a wealth of industry and strategic expertise and experience that will bring significant value to Nuvectis and contribute to the potentially bright future that we envision for the Company.”","length":454,"tagName":"p"},{"type":"text","content":"Dr. Sanchez noted, “I am pleased to join the Nuvectis Board at this pivotal time for the Company. The Company’s innovative approach to developing NXP900 for the potential use in advanced and treatment-resistant cancers, and the prospect of working with the seasoned management team and Board members, made the opportunity to join the Board compelling.”","length":352,"tagName":"p"},{"type":"text","content":"Dr. Sanchez brings 30+ years of multifaceted experience that uniquely integrates key healthcare perspectives including direct patient care as a medical doctor, researc...